Dinah Sah, PhD

Dr. Dinah Sah has 28 years of experience in research and drug development in the biotechnology industry, and currently serves on multiple scientific advisory boards for biotechnology and venture capital organizations. Dr. Sah most recently was Chief Scientific Officer at Voyager Therapeutics, focused on the discovery and development of AAV gene therapy for the treatment of severe neurological diseases. Prior to Voyager, she was Vice President of Research at Alnylam Pharmaceuticals and also served at Biogen and Signal Pharmaceuticals. Dr. Sah’s accomplishments include leadership of multiple programs from early research through Phase 1 clinical trials, and the discovery of novel therapeutic targets and drug candidates that advanced into clinical development.

Her leadership of drug discovery and development programs based on RNAi therapeutics resulted in the landmark demonstration of human proof-of-mechanism for this novel class of drugs in TTR amyloidosis patients which led to the approval of ONPATTRO® (patisiran). 

 

Dr. Sah is an inventor on more than 40 patents, and her publications across diverse research areas include articles in journals such as Nature Medicine, Nature Biotechnology, Nature Neuroscience, Molecular Therapeutics, Neuron, PNAS and the New England Journal of Medicine. Dr. Sah obtained a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Neurobiology from Harvard University. 

Dr. Dinah Sah has 28 years of experience in research and drug development in the biotechnology industry, and currently serves on multiple scientific advisory boards for biotechnology and venture capital organizations. Dr. Sah most recently was Chief Scientific Officer at Voyager Therapeutics. Prior to Voyager, she was Vice President of Research at Alnylam Pharmaceuticals and also served at Biogen and Signal Pharmaceuticals.